Equity Overview
Price & Market Data
Price: $22.46
Daily Change: +$1.46 / 6.50%
Daily Range: $19.83 - $22.46
Market Cap: $38,242,080
Daily Volume: 28,109
Performance Metrics
1 Week: 33.06%
1 Month: 37.71%
3 Months: 65.70%
6 Months: 124.6%
1 Year: -55.96%
YTD: 46.03%
Company Details
Employees: 29
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.